HYDROMORPHONE HYDROCHLORIDE

First approved in 1972

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H19NO3.ClH
Molecular Weight	321.799
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of HYDROMORPHONE HYDROCHLORIDE

Structure Search

SMILES

Cl.[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CCC2=O)=CC=C3O

InChI

InChIKey=XHILEZUETWRSHC-NRGUFEMZSA-N

InChI=1S/C17H19NO3.ClH/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18;/h2,4,10-11,16,19H,3,5-8H2,1H3;1H/t10-,11+,16-,17-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C17H19NO3
Molecular Weight	285.3377
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019034s029lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/11869661 | https://www.ncbi.nlm.nih.gov/pubmed/16433932

Hydromorphone (also known as dihydromorphinone and the brand name Dilaudid among others) is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low. The kidney excretes hydromorphone and its metabolites. Some metabolites may have greater analgesic activity than hydromorphone itself but are unlikely to contribute to the pharmacological activity of hydromorphone. With the exception of pruritus, sedation and nausea and vomiting, which may occur less after hydromorphone than after morphine, the side-effects of these drugs are similar. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. It also binds with kappa and delta receptors which are thought to mediate spinal analgesia, miosis and sedation.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Kappa opioid receptor 108 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16433932	Agonist 2678	279.0 nM [EC50]
Delta opioid receptor 77 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9301669	Partial Agonist 290
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18789923	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019034s029lbl.pdf	Palliative		Approved 8429	DILAUDID-HP Approved Use DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. DILAUDID-HP INJECTION is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Patients considered opioid tolerant are those who are taking for one week or longer,around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. Patients must remain on around-the-clock opioids while administering DILAUDID-HP Launch Date 1984

C_max

Value	Dose	Co-administered	Analyte	Population
5.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
23.7 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
81% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROMORPHONE HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
540 mg single, intrathecal Overdose Dose: 540 mg Route: intrathecal Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274	unhealthy, 27 n = 1 Health Status: unhealthy Condition: Pain Age Group: 27 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274	Disc. AE: Sleepiness, Nausea... AEs leading to discontinuation/dose reduction: Sleepiness Nausea Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274
2 mg 3 times / day multiple, intravenous Recommended Dose: 2 mg, 3 times / day Route: intravenous Route: multiple Dose: 2 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378	unhealthy, 40 n = 1 Health Status: unhealthy Condition: Pain Age Group: 40 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378	Disc. AE: Respiratory arrest... AEs leading to discontinuation/dose reduction: Respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378
4 mg 4 times / day multiple, oral (max) Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545	unhealthy, 67.7 n = 88 Health Status: unhealthy Condition: Pain Age Group: 67.7 Sex: M+F Population Size: 88 Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545	Disc. AE: Somnolence, Aspiration pneumonia... AEs leading to discontinuation/dose reduction: Somnolence (serious, 1.14%) Aspiration pneumonia (grade 5, 1.14%) Toxic skin eruption (serious, 1.14%) Nausea and vomiting (serious, 1.14%) Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545
10 mg single, intravenous Overdose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378	unhealthy n = 1 Health Status: unhealthy Condition: Pain Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378	Disc. AE: Cardio-respiratory arrest... AEs leading to discontinuation/dose reduction: Cardio-respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378
2 mg 6 times / day multiple, subcutaneous\|intramuscular Recommended Dose: 2 mg, 6 times / day Route: subcutaneous\|intramuscular Route: multiple Dose: 2 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf Page: p.1	Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf Page: p.1
4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	Disc. AE: Addiction, Abuse... AEs leading to discontinuation/dose reduction: Addiction Abuse Respiratory depression (grade 3-5) Withdrawal syndrome neonatal (grade 3-5) Coma (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Nausea	Disc. AE	540 mg single, intrathecal Overdose Dose: 540 mg Route: intrathecal Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274	unhealthy, 27 n = 1 Health Status: unhealthy Condition: Pain Age Group: 27 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274
Sleepiness	Disc. AE	540 mg single, intrathecal Overdose Dose: 540 mg Route: intrathecal Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274	unhealthy, 27 n = 1 Health Status: unhealthy Condition: Pain Age Group: 27 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15336340 Page: p.274
Respiratory arrest	grade 5 Disc. AE	2 mg 3 times / day multiple, intravenous Recommended Dose: 2 mg, 3 times / day Route: intravenous Route: multiple Dose: 2 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378	unhealthy, 40 n = 1 Health Status: unhealthy Condition: Pain Age Group: 40 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378
Aspiration pneumonia	grade 5, 1.14% Disc. AE	4 mg 4 times / day multiple, oral (max) Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545	unhealthy, 67.7 n = 88 Health Status: unhealthy Condition: Pain Age Group: 67.7 Sex: M+F Population Size: 88 Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545
Nausea and vomiting	serious, 1.14% Disc. AE	4 mg 4 times / day multiple, oral (max) Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545	unhealthy, 67.7 n = 88 Health Status: unhealthy Condition: Pain Age Group: 67.7 Sex: M+F Population Size: 88 Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545
Somnolence	serious, 1.14% Disc. AE	4 mg 4 times / day multiple, oral (max) Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545	unhealthy, 67.7 n = 88 Health Status: unhealthy Condition: Pain Age Group: 67.7 Sex: M+F Population Size: 88 Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545
Toxic skin eruption	serious, 1.14% Disc. AE	4 mg 4 times / day multiple, oral (max) Recommended Dose: 4 mg, 4 times / day Route: oral Route: multiple Dose: 4 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545	unhealthy, 67.7 n = 88 Health Status: unhealthy Condition: Pain Age Group: 67.7 Sex: M+F Population Size: 88 Sources: https://pubmed.ncbi.nlm.nih.gov/29659913 Page: p.545
Cardio-respiratory arrest	grade 5 Disc. AE	10 mg single, intravenous Overdose Dose: 10 mg Route: intravenous Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378	unhealthy n = 1 Health Status: unhealthy Condition: Pain Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21620461 Page: p.378
Respiratory depression	Disc. AE	2 mg 6 times / day multiple, subcutaneous\|intramuscular Recommended Dose: 2 mg, 6 times / day Route: subcutaneous\|intramuscular Route: multiple Dose: 2 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf Page: p.1
Abuse	Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1
Addiction	Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1
Respiratory depression	grade 3-5 Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1
Withdrawal syndrome neonatal	grade 3-5 Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1
Coma	grade 5 Disc. AE	4 mg 6 times / day multiple, oral Recommended Dose: 4 mg, 6 times / day Route: oral Route: multiple Dose: 4 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C8 911	CYP3A5 395

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021044lbl.pdf#page=6 Page: 6.0	weak [IC50 >50 uM]

Drug as victim

Target	Modality	Activity
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15268978/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5791	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5791
eMolecules	539218	https://www.emolecules.com/cgi-bin/more?vid=539218

PubMed

Title	Date	PubMed
Survey of pain management therapy provided for children with sickle cell disease.	1992 Apr	1373356
Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report.	1992 May	1376887
Assessment of biodegradable controlled release rod systems for pain relief applications.	2002	12003071
A convenient synthesis of delta(7,8)-morphinan-6-one and its direct oxidation to 14-hydroxy-delta(7,8)-morphinan-6-one.	2002 Aug 5	12113823
Epidural and intrathecal analgesia for cancer pain.	2002 Dec	12516896
Screening extemporaneously compounded intraspinal injections with the bacterial endotoxins test.	2002 Dec 15	12503341
New directions in pain management.	2002 Feb	12532190
Role of urine toxicology testing in the management of chronic opioid therapy.	2002 Jul-Aug	12479257
Clinical pharmacology of opioids for pain.	2002 Jul-Aug	12479250
The use of methadone for cancer pain.	2002 Jun	12170567
Pain management for joint arthroplasty: preemptive analgesia.	2002 Jun	12068423
The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat.	2002 Jun	12032023
The addition of hydromorphone to epidural fentanyl does not affect analgesia in early labour.	2002 Jun-Jul	12067873
Postthoracotomy pain management.	2002 May	12122825
Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient.	2002 May	12065064
Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.	2002 May	12007754
Separating politics and scientific research on heroin prescription.	2002 May 6	12057002
Pain and suffering in an adolescent with neuroblastoma.	2002 May-Jun	12027962
Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.	2002 Nov 18	12437765
Opioid rotation in the treatment of joint pain. A review of 67 cases.	2002 Oct	12477234
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.	2002 Oct	12423011
A field evaluation of five on-site drug-testing devices.	2002 Oct	12423006
Detection of cocaine analytes and opiates in nails from postmortem cases.	2002 Oct	12423005
Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.	2002 Oct	12357147
Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion.	2002 Sep	12222557
In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systems.	2003	12901434
Envenomation by the Mexican beaded lizard: a case report.	2003	12807305
Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.	2003	12662124
Morphine and hydromorphone for postoperative analgesia: focus on safety.	2003 Apr	12710006
Embolized crospovidone (poly[N-vinyl-2-pyrrolidone]) in the lungs of intravenous drug users.	2003 Apr	12692192
Calculating opioid dose conversions #36.	2003 Aug	14516504
Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002).	2003 Aug	12915905
Is the analgesic effect of systemic lidocaine mediated through opioid receptors?	2003 Aug	12859317
Comparison of morphine and hydromorphone analysis on reversed phase columns with different diameters.	2003 Aug 8	12899977
Hydromorphone transfer into breast milk after intranasal administration.	2003 Feb	12587803
Postoperative hypoxemia and hypercarbia in healthy dogs undergoing routine ovariohysterectomy or castration and receiving butorphanol or hydromorphone for analgesia.	2003 Feb 1	12564595
Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection.	2003 Feb 25	12535841
Catheter-associated masses in patients receiving intrathecal analgesic therapy.	2003 Jan	12505950
Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations.	2003 Jul	12850649
Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.	2003 Jul	12818953
[Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely].	2003 Jul 10	14587190
Management of postoperative pain after T6 corpectomy: use of epidural bupivacaine and sufentanil--a case report.	2003 Jun	12847945
Oral oxycodone: new preparation. No better than oral morphine.	2003 Jun	12825566
Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test.	2003 Mar	12745417
Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.	2003 Mar	12570846
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.	2003 Nov	12902992
Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury model.	2003 Nov 14	14572875
[Combined use of intrathecal morphine and diclofenac suppository for postoperative analgesia after caesarean section].	2003 Oct	14598667
The use of long-acting opioids in chronic pain management.	2003 Sep	14567201
Oral vs. i.v. hydromorphone. Add a measure of caution.	2003 Sep	14562820

Patents

Sample Use Guides

In Vivo Use Guide

Subcutaneous or Intramuscular Administration: The usual starting dose of DILAUDID INJECTION is 1 mg to 2 mg every 2 to 3 hours as necessary. Depending on the clinical situation, the initial starting dose may be lowered in patients who are opioid naïve. Intravenous Administration: The initial starting dose is 0.2 to 1 mg every 2 to 3 hours. Intravenous administration should be given slowly, over at least 2 to 3 minutes, depending on the dose. The initial dose should be reduced in the elderly or debilitated and may be lowered to 0.2 mg.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:00:27 GMT 2023` Edited by `admin` on `Fri Dec 15 15:00:27 GMT 2023`
Record UNII	L960UP2KRW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYDROMORPHONE HYDROCHLORIDE

Common Name

English

HYDROMORPHONE HYDROCHLORIDE CII

Common Name

English

4,5α-Epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride

Systematic Name

English

HYDROMORPHONE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

DIHYDROMORPHINONE HYDROCHLORIDE

Common Name

English

Hydromorphone hydrochloride [WHO-DD]

Common Name

English

HYDROMORPHONE HYDROCHLORIDE CII [USP-RS]

Common Name

English

HYDROMORPHONE HYDROCHLORIDE [MART.]

Common Name

English

HYDROMORPHONE HYDROCHLORIDE [JAN]

Common Name

English

HYDROMORPHONE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

HYDROMORPHONE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

HYDROMORPHONE HYDROCHLORIDE [VANDF]

Common Name

English

EXALGO

Brand Name

English

PALLADONE

Brand Name

English

NSC-117862

Code

English

DILAUDID

Brand Name

English

HYDROMORPHONE HYDROCHLORIDE [MI]

Common Name

English

MORPHINAN-6-ONE, 4,5-EPOXY-3-HYDROXY-17-METHYL-, HYDROCHLORIDE, (5.ALPHA.)-

Systematic Name

English

HYDROMORPHONE HCL

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

499415